| 曹 玲,闫卫红,丁智斌,徐心田,宋艳丽,沈志丽.复方活脑舒胶囊联合多奈哌齐对帕金森病轻度认知功能障碍患者认知功能和血清脑神经递质的影响[J].,2024,(8):1482-1485 |
| 复方活脑舒胶囊联合多奈哌齐对帕金森病轻度认知功能障碍患者认知功能和血清脑神经递质的影响 |
| Effect of Compound Huonaoshu Capsule and Donepezil on Cognitive Function and Serum Cranial Nerves Transmitters in Patients with Mild Cognitive Impairment of Parkinson's Disease |
| 投稿时间：2023-10-06 修订日期：2023-10-28 |
| DOI：10.13241/j.cnki.pmb.2024.08.015 |
| 中文关键词: 复方活脑舒胶囊 多奈哌齐 帕金森 认知功能障碍 脑神经递质 |
| 英文关键词: Compound huonaoshu capsule Donepezil Parkinson's disease Cognitive dysfunction Brain neurotransmitters |
| 基金项目:山西省基础研究计划自由探索类项目（20210302123408） |
|
| 摘要点击次数: 323 |
| 全文下载次数: 216 |
| 中文摘要: |
| 摘要 目的：观察复方活脑舒胶囊联合多奈哌齐对帕金森病（PD）轻度认知功能障碍（PD-MCI）患者认知功能和血清脑神经递质的影响。方法：选择2021年3月~2022年12月期间在我院接受治疗的PD-MCI患者128例。按照随机数字表法将患者分为对照组（多奈哌齐治疗）和研究组（复方活脑舒胶囊联合多奈哌齐治疗），各为64例。对比两组疗效、简易智能精神状态检查量表（MMSE）、蒙特利尔认知评估量表（MoCA）、日常生活能力量表（ADL）评分和血清脑神经递质[5-羟色胺（5-HT）、乙酰胆碱（Ach）、多巴胺（DA）]。同时统计两组治疗期间不良反应发生率。结果：与对照组相比，研究组的临床总有效率明显升高（P<0.05）。治疗12周后，研究组的MMSE、MoCA、ADL评分高于对照组（P<0.05）。治疗12周后，研究组的5-HT、Ach、DA高于对照组（P<0.05）。两组不良反应发生率对比未见差异（P>0.05）。结论：复方活脑舒胶囊联合多奈哌齐治疗PD-MCI患者，可有效改善患者的认知功能，改善血清脑神经递质水平，提高患者的日常生活自理能力。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the effect of Fufang Huonaoshu capsule combined with Donepezil on cognitive function and serum brain neurotransmitters in patients with Parkinson's disease (PD) with mild cognitive impairment (PD-MCI). Methods: 128 patients with PD-MCI who received treatment in our hospital from March 2021 to December 2022 were selected. The patients were divided into a control group (treated with Donepezil) and a study group (treated with compound Huonaoshu capsule and Donepezil) according to the method of random number table, with 64 cases in each group. The efficacy, the Mini Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), the Activity of Daily Living Scale (ADL) and serum brain neurotransmitters [5-HT, Acetylcholine, dopamine] were compared between the two groups. Simultaneously observe the incidence of adverse reactions during treatment in both groups. Results: Compared with the control group, the clinical total effective rate of the study group was significantly increased (P<0.05). After 12 weeks of treatment, the MMSE, MoCA, and ADL scores of the study group were higher than those of the control group (P<0.05). After 12 weeks of treatment, the 5-HT, Ach, and DA levels in the study group were higher than those in the control group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Fufang Huonaoshu capsule combined with Donepezil can effectively improve the cognitive function of patients with PD-MCI, improve the serum brain neurotransmitter level, and improve the daily living ability of patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
